
Our Pipeline
By focusing on treatments for CNS conditions, we strive to meet the needs of patients by providing innovative solutions. Below is an overview of our pipeline.
AVP-786
Description
The objectives of the program are to evaluate the efficacy, safety and tolerability of AVP-786 compared to placebo, for the treatment of agitation in patients with Alzheimer’s Dementia.
Description
The objectives of the program are to evaluate the efficacy, safety and tolerability of AVP-786 as an adjunctive treatment compared to placebo in patients with schizophrenia who have negative symptoms.
Description
The objectives of the program are to evaluate the efficacy, safety and tolerability of AVP-786 compared to placebo, for the treatment of patients with intermittent explosive disorder (IED).
Description
The objectives of the program are to evaluate the efficacy, safety and tolerability of AVP-786 compared to placebo, for the treatment of neurobehavioral disinhibition such as aggression, agitation and irritability of patients with traumatic brain injury.
People who work here are really passionate about what they do. They believe in their work and they’re committed to ensure that we find the right answers to what we are working on. Everybody wants to challenge themselves.
MLR-AVN-US-0336-0220